Friday, 16 October 2026European Markets

MAGNORA Stock 9.8% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with MAGNORA (MGN.OL) rising 9.8% to kr26.90 on Friday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.97% to kr1,213.11, following the last session's downward trend on what was a somewhat positive trend trading session today.

MAGNORA's last close was kr24.50, 14.19% below its 52-week high of kr28.55.

About MAGNORA

Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr0.22.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 122.27. Meaning, the purchaser of the share is investing kr122.27 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.29%.

Moving Average

MAGNORA's value is way above its 50-day moving average of kr22.42 and way higher than its 200-day moving average of kr22.66.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2596.6%, now sitting on 91.7M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MAGNORA's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

MAGNORA's stock is valued at kr26.90 at 22:33 EST, under its 52-week high of kr28.55 and way above its 52-week low of kr16.30.

More news about MAGNORA (MGN.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com